Horime (Ezetimibe, Rosuvastatin Calcium)

Horime is indicated for the treatment of abnormal lipid profiles in adult patients who require additional cholesterol lowering.

• Primary hypercholesterolemia, including familial forms, when diet and lifestyle changes are insufficient.
• Mixed dyslipidemia characterized by elevated LDL‑cholesterol and triglycerides.
• Patients with high cardiovascular risk who need combined reduction of LDL‑C and non‑HDL‑C.
• Adjunct therapy for individuals already on a statin who need further LDL‑C lowering.
• Secondary prevention of cardiovascular events in patients with established atherosclerotic disease.

• Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter on the brush border of enterocytes, reducing the intestinal uptake of dietary and biliary cholesterol. Rosuvastatin calcium competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL‑cholesterol. The combined action results in a greater overall reduction of plasma cholesterol than either component alone.

Adverse reactions to Horime have been observed in clinical practice; they can be mild and transient or, less frequently, severe and potentially life‑threatening. The frequency of each event varies.

Common

• Headache, dizziness, or fatigue, which are usually mild and transient.
• Upper abdominal discomfort, nausea, or diarrhea that may resolve without intervention.
• Myalgia or mild muscle cramps without significant creatine kinase elevation.
• Transient elevations in liver enzymes (ALT/AST) that typically return to baseline.
• Dry mouth or altered taste sensation occasionally reported.
• Insomnia or sleep disturbances noted in some patients.
• Elevated blood glucose levels in individuals with pre‑existing glucose intolerance.

Serious

• Clinically significant myopathy or rhabdomyolysis, which can lead to severe muscle injury.
• Severe liver injury or hepatitis presenting with marked enzyme elevations.
• Allergic reactions such as rash, angioedema, or anaphylaxis requiring immediate medical attention.
• Acute renal failure secondary to rhabdomyolysis in rare cases.

Before initiating Horime, clinicians should evaluate patient history and laboratory parameters to identify conditions that may increase the risk of adverse outcomes.

• Assess baseline liver function tests; avoid use in patients with active hepatic disease.
• Check creatine kinase levels if there is a history of muscle disorders or concomitant statin therapy.
• Use caution in patients with renal impairment; dose adjustment may be required.
• Avoid in pregnant or breastfeeding women unless benefits outweigh risks.
• Review concomitant medications for potential drug‑drug interactions, especially CYP3A4 inhibitors.
• Monitor lipid profile and glucose levels periodically during therapy.

Horime may interact with other medicines, potentially altering its efficacy or increasing the risk of toxicity.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which can markedly reduce rosuvastatin exposure.
• Cyclosporine or gemfibrozil, which significantly increase rosuvastatin plasma concentrations and risk of myopathy.
• Concomitant use with high-dose niacin, which can increase the risk of hepatotoxicity.

Use with caution

• Other lipid‑lowering agents (e.g., fibrates, niacin) that may raise the chance of muscle toxicity.
• Anticoagulants like warfarin, as rosuvastatin can modestly affect INR.
• Antacids containing aluminum or magnesium, which may decrease ezetimibe absorption.
• Macrolide antibiotics (e.g., clarithromycin) that inhibit CYP3A4 and may raise rosuvastatin levels.
• Drugs that affect bile acid metabolism (e.g., cholestyramine) may reduce ezetimibe absorption.